ArticleOxford medical case reports2025
Durable clinical and metabolic response to Trastuzumab Deruxtecan in heavily Pretreated male HER2-low metastatic breast cancer: a case report.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Male breast cancer (MBC), accounting for < 1% of all breast malignancies, remains underrepresented in clinical trials evaluating human epidermal growth factor receptor 2 (HER2)-targeted therapies. Most MBCs are hormone receptor-positive (HR+), with a high rate of HER2-low expression. However, men were excluded from clinical trials evaluating HER2-directed agents, which is an absolute evidence gap. Case Report: We present the case of a 76-year-old man with heavily pretreated, HR+/HER2-low (immunohistochemistry [IHC] 1+) metastatic breast cancer (mBC) who achieved a complete metabolic response (CMR) following four cycles of trastuzumab deruxtecan (T-DXd) without any grade ≥ 2 (G ≥ 2) toxicity. Conclusion: This case highlights the potential efficacy and tolerability of T-DXd in men and challenges the systematic exclusion of male patients from clinical trials involving HER2-low mBC. We advocate routine HER2-low testing and gender-inclusive trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.